Ron Weiss, MIT

• Martin Fussenegger, ETH: "Prosthetic networks: A new treatment strategy for metabolic disorders"
• Pam Silver, Harvard: "Designing systems to interrogate and re-program cell state"
• Philip Gregory, Sangamo BioSciences: "Genome editing with zinc finger nucleases"

• Ron Weiss, MIT: "From parts to modules to therapeutic systems using mammalian synthetic biology"
• Philip Dormitzer, Novartis: "Synthetic vaccines: Synthetic biology approaches the clinic"

• Advances in DNA assembly and delivery
• Advances in transcriptional regulation
• Advances in sensors and actuators
• Advances in non-transcriptional regulation

• Doug Melton, Harvard: "Multiple routes to investigate type 1 diabetes"
• David Schaffer, Berkeley: “Molecular engineering and evolution of new viruses for mammalian gene delivery”
• Harvey Lodish, MIT: "Genetically and chemically modified red blood cells as novel therapeutics, immunomodulatory agents, and imaging probes"
• Tyler Jacks, MIT: "Modeling cancer in the mouse"

• Opportunities and challenges in cancer
• Opportunities and challenges in stem cells and tissue engineering
• Opportunities and challenges in vaccination and infectious disease
• Opportunities and challenges in diabetes and metabolic diseases
• Opportunities and challenges in neurosciences
• Opportunities and challenges in scientific inquiry
• Opportunities and challenges in drug screening

• James Collins, Boston University: "Mammalian synthetic biology and biomedical applications"
• Christina Smolke, Stanford: "RNA-based control systems for regulating cell fate in human cells"
• Linda Griffith, MIT: "Human physiome on a chip + synthetic biology = Better drugs, faster and cheaper"